摘要
目的:观察支气管哮喘患者呼出气冷凝液(EBC)中半胱氨酰白三烯C4(LTC4)水平及孟鲁司特治疗后的变化。方法:选择哮喘非急性发作期患者30例,均予孟鲁司特10 mg,每晚一次口服,疗程1月,分别于治疗前及治疗后检测EBC中LTC4水平,同时测定肺功能,另选择30例健康人为对照组。结果:哮喘组治疗前LTC4水平(55.17±17.02)ng/ml,显著高于正常对照组(17.15±7.48)ng/ml,差异有统计学意义(P<0.01)。哮喘组治疗后LTC4水平为(38.36±14.03)ng/ml,仍高于正常对照组,差异有统计学意义(P<0.01)。哮喘组治疗前LTC4水平显著高于治疗后,差异有统计学意义(P<0.01)。结论:检测哮喘患者EBC中LTC4水平可简便安全监测哮喘的气道炎症,孟鲁司特是一种有效的气道炎症抑制剂。
Objective：To investigate the level of leukotrienes C4（LTC4） in exhaled breath condensate（EBC） of patients with asthma and the effect of inflammatory factors ＇after montelukast treatment. Methods：Thirty patients with asthma were enrolled and given 10 mg montelukast once each night for one month. Before therapy and one month lat- er, the levels of LTC4 in EBC were measured. Another 30 healthy controls were selected as control group. Results： LTC4 levels were significantly higher in the asthma patients before and after treatment compared with the control sub- jects. The level of LTC4 was significantly decreased in patients with asthma after treatment. Conclusion： Detecting the LTC4 level in EBC can monitor asthmatic airway telukast can decrease the level of LTC4,which is an inflammation,which is convenient,noninvasive and sate. Mon- effective anti- inflammatory reagent.
出处
《中国卫生检验杂志》
北大核心
2013年第2期390-391,394,共3页
Chinese Journal of Health Laboratory Technology
基金
绍兴市科学技术局科技计划(2009A33028)
